Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of apremilast in active ankylosing spondylitis
2011-001555-37Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Apremilast with Placebo (2 arms). Primary endpoint: ASAS 20 response. Started Apr 2012; status: completed.
02
Drugs
apremilast
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2011-001555-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001555-37.